Activity Overview
Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema due to retinal vein occlusion (RVO) are significant drivers of vision loss—and they put substantial burdens on patients, including the need for regular anti-VEGF injections to treat them. In this program, a panel of experts will discuss cases while highlighting answers to questions regarding treatment-naïve and suboptimally responding patients, extended treatment intervals in RVO, biosimilars, and much more. This educational activity is an archive of the live presentation held on October 9, 2026.
Target Audience
This educational activity is directed toward retina specialists, comprehensive ophthalmologists, and other eye care professionals involved in the treatment of neovascular retinal disease, including nAMD, DME, and RVO.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Differentiate between biosimilars and next-generation anti-VEGF agents regarding clinical evidence, approved dosing regimens, and extended-interval capabilities
- Apply long-term clinical trial data and comparative analyses to guide treatment selection and switching decisions in the current anti-VEGF landscape
- Develop evidence-based strategies for treatment selection when multiple anti-VEGF options are available
Carl Danzig, MD, FASRS
Vitreoretinal Surgeon, Fort Lauderdale Eye Institute
Affiliate Assistant Professor of Clinical Biomedical Science
Charles E. Schmidt College of Medicine
Florida Atlantic University
Fort Lauderdale, FL
Disclosures: Advisor, Consultant, Fee for Service Recipient: 4DMT, AbbVie, Able Tx, Adverum, Apellis, Beacon Therapeutics, Cognition, EyeBio, EyePoint, Genentech, Intellia Therapeutics, Iveric Bio/Astellas, Lexitas, Mighty Therapeutics, Ocular Therapeutix, Oculis, Opthea, Outlook Therapeutics, Recens Medical, Regeneron, Roche, Samsung Bioepis, Sanofi, Unity; Speakers Bureau: Astellas; Grant/Research Funding: 4DMT, Adverum/Eli Lilly, Alexion, Annexon, Apellis, Aviceda, Bayer, Boehringer Ingelheim, Cognition, EyeBio/Merck, EyePoint, Genentech, Iveric Bio/Astellas, Ocular Therapeutix, Oculis, Regeneron, RegenxBio, Roche, Unity.
Sruthi Arepalli, MD
Assistant Professor of Ophthalmology
Associate Residency Program Director
Emory Eye Center, Emory University School of Medicine
Atlanta, GA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Alimera, Genentech.
Priya Vakharia, MD, FASRS
Partner, Retina Vitreous Associates of Florida
Collaborative Assistant Professor, University of South Florida/Morsani College of Medicine
Retina Residency Program Director at HCA Bayonet Point Ophthalmology Residency Program
Tampa, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Bausch + Lomb, Genentech, Gyroscope, Heidelberg; Investigator: Alkahest, Annexon, AsclepiX, Bayer, Chengdu (PANDA trial stopped in April 2021), EyePoint, Gemini, Genentech, Gyroscope, Ionis, Iveric Bio, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, Opthea, Recens Medical, Regeneron, RegenxBio, Unity.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here